Wen-Hai Shao1, Daniel H Shu2, Yuxuan Zhen2, Brendan Hilliard2, Stephen O Priest2, Matteo Cesaroni2, Jenny P-Y Ting3, Philip L Cohen4. 1. Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania. wshao@temple.edu. 2. Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania. 3. University of North Carolina at Chapel Hill. 4. Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania. philco@temple.edu.
Abstract
OBJECTIVE: Increased levels of type I interferon (IFN) and type I IFN-regulated genes are found in patients with systemic lupus erythematosus (SLE) and may be central to its pathogenesis. Mitochondrial antiviral signaling protein (MAVS) is a key regulator of type I IFN that undergoes a dramatic prion-like aggregation and self propagates the activation signal from viral RNA to amplify downstream IFN production. We undertook this study to determine whether such MAVS aggregates might play a role in the sustained increased production of type I IFN in SLE. METHODS: Peripheral blood mononuclear cells were isolated and mitochondrial extracts were prepared. MAVS aggregation was detected by semidenatured agarose gel electrophoresis and confirmed by immunofluorescence staining. MAVS-associated signaling proteins were analyzed by Western blotting. MAVS aggregation-associated gene expression signature was analyzed by microarray. RESULTS: In blood cells from 22 of 67 SLE patients, essentially all MAVS was in a high molecular weight aggregated form. None of 6 rheumatoid arthritis patients and only 3 of 33 healthy controls had abnormal MAVS. Compared to MAVS aggregate-negative patients, MAVS aggregate-positive SLE patients had significantly higher serum levels of IFNβ and significantly increased levels of autoantibodies against Sm and U1 RNP. Gene array data revealed a characteristic gene expression pattern in these patients, with altered expression of genes involved in IFN signaling and membrane trafficking. CONCLUSION: Persistent MAVS aggregates may lead to increased type I IFN production and result in unmitigated signals leading to autoimmunity.
OBJECTIVE: Increased levels of type I interferon (IFN) and type I IFN-regulated genes are found in patients with systemic lupus erythematosus (SLE) and may be central to its pathogenesis. Mitochondrial antiviral signaling protein (MAVS) is a key regulator of type I IFN that undergoes a dramatic prion-like aggregation and self propagates the activation signal from viral RNA to amplify downstream IFN production. We undertook this study to determine whether such MAVS aggregates might play a role in the sustained increased production of type I IFN in SLE. METHODS: Peripheral blood mononuclear cells were isolated and mitochondrial extracts were prepared. MAVS aggregation was detected by semidenatured agarose gel electrophoresis and confirmed by immunofluorescence staining. MAVS-associated signaling proteins were analyzed by Western blotting. MAVS aggregation-associated gene expression signature was analyzed by microarray. RESULTS: In blood cells from 22 of 67 SLEpatients, essentially all MAVS was in a high molecular weight aggregated form. None of 6 rheumatoid arthritispatients and only 3 of 33 healthy controls had abnormal MAVS. Compared to MAVS aggregate-negative patients, MAVS aggregate-positive SLEpatients had significantly higher serum levels of IFNβ and significantly increased levels of autoantibodies against Sm and U1 RNP. Gene array data revealed a characteristic gene expression pattern in these patients, with altered expression of genes involved in IFN signaling and membrane trafficking. CONCLUSION: Persistent MAVS aggregates may lead to increased type I IFN production and result in unmitigated signals leading to autoimmunity.
Authors: Irma E Cisneros; Mert Erdenizmenli; Kathryn A Cunningham; Slobodan Paessler; Kelly T Dineley Journal: Neuropharmacology Date: 2018-03-23 Impact factor: 5.250
Authors: Sang-Hun Kim; Hyeon Jun Shin; Chang Min Yoon; Sei Won Lee; Lokesh Sharma; Charles S Dela Cruz; Min-Jong Kang Journal: Am J Respir Cell Mol Biol Date: 2021-05 Impact factor: 6.914
Authors: Ralph C Budd; Christopher D Scharer; Ramiro Barrantes-Reynolds; Scott Legunn; Karen A Fortner Journal: Antioxid Redox Signal Date: 2021-11-09 Impact factor: 8.401
Authors: Christian Lood; Tomas Mustelin; Kennedy C Ukadike; Kathryn Ni; Xiaoxing Wang; Martin S Taylor; John LaCava; Lauren M Pachman; Mary Eckert; Anne Stevens Journal: Arthritis Res Ther Date: 2021-05-29 Impact factor: 5.156